Randomized trial · people
NMN (MIB-626) raised blood NAD levels in older adults over 14 days
Checked against the paper Randomized trialPublished by PepVault
The takeaway
This trial shows that this specific pharmaceutical-grade NMN raised blood NAD in older adults over 14 days, with more NAD at the higher dose, but it does not show any health benefit.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 32
- Published
- 2023
- Journal
- J Gerontol A Biol Sci Med Sci
What they tested
The team tested how MIB-626, an oral form of NMN (nicotinamide mononucleotide), moves through the body and how it changes blood NAD and related compounds.
How the study was done
A double-blind, placebo-controlled randomized trial in 32 overweight or obese adults aged 55-80. They took 1 000 mg of MIB-626 once daily, 1 000 mg twice daily, or a placebo (a dummy pill) for 14 days, and blood NMN, NAD and related compounds were measured with liquid chromatography-tandem mass spectrometry, a lab method for measuring compounds.

What they found
On day 14, blood NMN was higher in both MIB-626 groups than in the placebo group. Measured as total exposure over the sampling period (mean AUClast), blood NMN was 1.7-times above baseline in the once-daily arm and 3.7-times above baseline in the twice-daily arm. Blood NAD rose substantially, and the rise was larger at the higher dose. NAD-related compounds were higher on days 8 and 14 than at baseline, very little unchanged NMN showed up in urine, and side effects were about as common as on placebo.
What it doesn’t show
This was a small, 14-day trial in overweight or obese adults aged 55-80, so it does not show long-term safety or how other groups respond. It measured blood levels of NMN and NAD, not health outcomes like strength, weight or disease.
The paper
Pencina et al. MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of β-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults. J Gerontol A Biol Sci Med Sci. 2023.
The compounds
More studies on NAD+
- NAD+: NR and NMN, not nicotinamide, raised blood NAD+ in 14 daysRandomized trial · people · 2026
- NAD+ improved LVEF at 1 month in ischemic heart failureRandomized trial · people · 2026
- NMN raised serum nicotinamide over 12 weeks in middle-aged adultsRandomized trial · people · 2023
- NMN supplements raised blood NAD+ levels in healthy older menRandomized trial · people · 2022
- NMN raised muscle insulin sensitivity in women with prediabetesRandomized trial · people · 2021
- NAD+ rose with nicotinamide riboside in a 6-week crossover trialRandomized trial · people · 2018
- Every study on NAD+
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.